S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Critical asset just had biggest fall on record (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
Tech Genius Reveals #1AI Stock For 2024 (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Tech Genius Reveals #1AI Stock For 2024 (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Critical asset just had biggest fall on record (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
Tech Genius Reveals #1AI Stock For 2024 (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Tech Genius Reveals #1AI Stock For 2024 (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Critical asset just had biggest fall on record (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
Tech Genius Reveals #1AI Stock For 2024 (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Tech Genius Reveals #1AI Stock For 2024 (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Critical asset just had biggest fall on record (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
Tech Genius Reveals #1AI Stock For 2024 (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Tech Genius Reveals #1AI Stock For 2024 (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
NASDAQ:VXRT

Vaxart (VXRT) Stock Price, News & Analysis

$1.41
+0.18 (+14.63%)
(As of 02/21/2024 ET)
Today's Range
$1.25
$1.45
50-Day Range
$0.56
$1.41
52-Week Range
$0.53
$1.59
Volume
5.37 million shs
Average Volume
2.19 million shs
Market Capitalization
$216.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

Vaxart MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
112.8% Upside
$3.00 Price Target
Short Interest
Bearish
7.24% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.59) to ($0.47) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.32 out of 5 stars

Medical Sector

787th out of 932 stocks

Biological Products, Except Diagnostic Industry

138th out of 159 stocks


VXRT stock logo

About Vaxart Stock (NASDAQ:VXRT)

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase II clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine, an oral vaccine platform, which is in preclinical stage; coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection; human papillomavirus therapeutic vaccine that targets HPV 16 and HPV 18 for cervical cancers and precancerous cervical dysplasia. The company has license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.

VXRT Stock Price History

VXRT Stock News Headlines

Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Vaxart, Inc. Announces Management Change
Here's Why Vaxart (NASDAQ:VXRT) Must Use Its Cash Wisely
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Vaxart (VXRT) Receives a Buy from Cantor Fitzgerald
Convert Australian Dollar To Nigerian Naira
Convert Australian Dollar To Nepalese Rupee
See More Headlines
Receive VXRT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaxart and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
2/22/2024
Next Earnings (Estimated)
3/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:VXRT
Previous Symbol
NASDAQ:NABI
Employees
164
Year Founded
2004

Price Target and Rating

Average Stock Price Target
$3.00
High Stock Price Target
$4.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+112.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-107,760,000.00
Net Margins
-2,141.68%
Pretax Margin
-2,139.20%

Debt

Sales & Book Value

Annual Sales
$110,000.00
Book Value
$0.84 per share

Miscellaneous

Free Float
148,849,000
Market Cap
$216.36 million
Optionable
Optionable
Beta
0.43

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for March 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Michael J. Finney Ph.D. (Age 64)
    Interim CEO & Director
    Comp: $50.52k
  • Dr. Sean N. Tucker Ph.D. (Age 55)
    Senior VP & Chief Scientific Officer
    Comp: $481.52k
  • Dr. James F. Cummings M.D. (Age 57)
    Chief Medical Officer
    Comp: $526.96k
  • Mr. Phillip Eric Lee (Age 36)
    CFO, Principal Financial Officer & Principal Accounting Officer
  • Dr. Raymond D. Stapleton Jr. (Age 53)
    Ph.D., Chief Technology Officer
  • Mr. Edward B. Berg (Age 59)
    Senior VP & General Counsel
  • Ms. Sarah Caravalho Khan
    VP & Head of Human Resources
  • Ms. Shaily Jaini Garg
    Senior Vice President of Clinical Development & Project Management
  • Dr. Rajesh Kapoor Ph.D.
    Senior Vice President of Quality














VXRT Stock Analysis - Frequently Asked Questions

Should I buy or sell Vaxart stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vaxart in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VXRT shares.
View VXRT analyst ratings
or view top-rated stocks.

What is Vaxart's stock price target for 2024?

2 Wall Street research analysts have issued 12-month price objectives for Vaxart's stock. Their VXRT share price targets range from $2.00 to $4.00. On average, they predict the company's stock price to reach $3.00 in the next year. This suggests a possible upside of 112.8% from the stock's current price.
View analysts price targets for VXRT
or view top-rated stocks among Wall Street analysts.

How have VXRT shares performed in 2024?

Vaxart's stock was trading at $0.5728 on January 1st, 2024. Since then, VXRT shares have increased by 146.2% and is now trading at $1.41.
View the best growth stocks for 2024 here
.

When is Vaxart's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024.
View our VXRT earnings forecast
.

How were Vaxart's earnings last quarter?

Vaxart, Inc. (NASDAQ:VXRT) issued its quarterly earnings results on Thursday, November, 4th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.14). The biotechnology company earned $0.20 million during the quarter, compared to analysts' expectations of $0.12 million. Vaxart had a negative net margin of 2,141.68% and a negative trailing twelve-month return on equity of 99.74%. The firm's revenue was down 24.5% compared to the same quarter last year.

When did Vaxart's stock split?

Shares of Vaxart reverse split on the morning of Wednesday, February 14th 2018. The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 9 shares after the split.

What other stocks do shareholders of Vaxart own?
Who are Vaxart's major shareholders?

Vaxart's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.59%), GSA Capital Partners LLP (0.32%), Northern Trust Corp (0.22%), Raymond James Financial Services Advisors Inc. (0.13%), Charles Schwab Investment Management Inc. (0.10%) and Private Portfolio Partners LLC (0.07%). Insiders that own company stock include Fuad Ahmad, Margaret Echerd, Robert A Yedid, Sean Tucker, W Mark Watson and Wouter Latour.
View institutional ownership trends
.

How do I buy shares of Vaxart?

Shares of VXRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VXRT) was last updated on 2/22/2024 by MarketBeat.com Staff